Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: First evidence of more than 2 years

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 5, 2010, Pages 400-403

  Jetsrisuparb, Arunee ^a   Komvilaisak, Patcharee ^a   Wiangnon, Surapon ^a   Jetsrisuparb, Charoon ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Combined deferasirox and desferrioxamine; Deferasirox; Desferrioxamine; Treatment of iron overload; Treatment of thalas semia

Indexed keywords

ASCORBIC ACID; DEFERASIROX; DEFEROXAMINE; FERRITIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; SIDEROPHORE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BETA THALASSEMIA; BLEEDING; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; LEUKOPENIA; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; BLOOD; DRUG COMBINATION; SURVIVAL RATE; THALASSEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BENZOIC ACIDS; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; RETROSPECTIVE STUDIES; SIDEROPHORES; SURVIVAL RATE; THALASSEMIA; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 77955891235     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e015b0     Document Type: Article

References (20)

1. Weatherall DJ, Clegg JB. Thalassemia syndromes. 4th ed. Oxford: Blackwell; 2001.
2. Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassemia major. Br J Haematol. 1995;89: 473-478.
3. Cazzola M, Borgna-Pignatti C, Locatelli F, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion. 1997;37: 135-140.
4. Cappellini MD, Cohen A, Eleftheriou A, et al. eds. Guidelines for the clinical management of Thalassemia. 2nd ed. Nicosia: Thalassemia International Federation; 2007.
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89: 1187-1193.
6. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331: 567-573.
7. Steinhauser S, Heinz U, Bartholoma M, et al. Complex formation of ICL670 and related ligands with Fe III and Fe II. Eur J Inorg Chem. 2004;21: 4177-4192.
8. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361: 1597-1602.
9. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelatingagent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43: 565-572.
10. Yang LP, Keam SJ, Keating GM. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67: 2211-2230. Review.
11. Wu KH, Chang JS, Tsai CH, et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol. 2004;83: 471-473.
12. Wonke B, Wright G, Hollbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haemato. 1998;103: 361-364.
13. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalasse- mia patients. Br J Haematol. 2003;121: 187-189.
14. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90: 1309-1314.
15. Daar S, Taher A, Pathare A, et al. Plasma LPL in thalassemia patients before and after treatment with Deferasirox (Exjade, ICL670). Blood. 2005;106: 758a. (Abstract 2697).
16. Wood WG. Hemoglobin analysis. In: Weatherall DJ, ed. The Thalassemia. New York: Churchill-Livingstone; 1983: 31-37.
17. Fucharoen G, Fucharoen S. Rapid and simultaneous non-radioactive method for detecting alpha-thalassemia 1 (SEA type) and Hb Constant Spring gene. Eur J Haematol. 1994;53: 186-187.
18. Fucharoen S, Fucharoen G, Ratanasiri T, et al. A simple non-radioactive assay for hemoglobin E gene in prenatal diagnosis. Clin Chim Acta. 1994;229: 197-203.
19. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107: 3455-3462.
20. Olivieri NF, Briltenhem GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89: 739-761.